Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study (Q36245589)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study (English)

1 reference

Europe PubMed Central

13 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

Mitch Dowsett

1 reference

Europe PubMed Central

13 August 2017

4

object named as

Jack Cuzick

1 reference

Europe PubMed Central

13 August 2017

author name string

Katja Lundgren

1

1 reference

Europe PubMed Central

13 August 2017

Matthew Brown

2

1 reference

Europe PubMed Central

13 August 2017

Silvia Pineda

3

1 reference

Europe PubMed Central

13 August 2017

Janine Salter

5

1 reference

Europe PubMed Central

13 August 2017

Lila Zabaglo

6

1 reference

Europe PubMed Central

13 August 2017

Anthony Howell

7

1 reference

Europe PubMed Central

13 August 2017

Göran Landberg

9

1 reference

Europe PubMed Central

13 August 2017

TransATAC investigators

10

1 reference

Europe PubMed Central

13 August 2017

publication date

4 April 2012

1 reference

Europe PubMed Central

13 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

13 August 2017

14

1 reference

Europe PubMed Central

13 August 2017

2

1 reference

Europe PubMed Central

13 August 2017

R57

1 reference

Europe PubMed Central

13 August 2017

https://scigraph.springernature.com/pub.10.1186/bcr3161

0 references

Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Cyclin D1, EMS1 and 11q13 amplification in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Cellular and molecular pharmacology of antiestrogen action and resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Recent advances in endocrine therapy of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

CDK-independent activation of estrogen receptor by cyclin D1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

1 October 2017

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

29 June 2018

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

29 June 2018

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Cyclin D1 and prognosis in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Determination of the prognostic value of cyclin D1 overexpression in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446392

22 September 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1186%2FBCR3161

21 January 2018

Cyclin D1 protein expression and function in human breast cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR3161

21 January 2018

Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Wilcoxon-type test for trend

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and amplification of cyclin genes in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens

1 reference

https://pubmed.ncbi.nlm.nih.gov/22475046

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR3161

1 reference

Europe PubMed Central

13 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36245589&oldid=1966932861"